NASDAQ:SCNI Scinai Immunotherapeutics Q4 2025 Earnings Report $0.24 +0.00 (+1.04%) Closing price 08/14/2026 04:00 PM EasternExtended Trading$0.24 0.00 (-0.21%) As of 08/14/2026 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Scinai Immunotherapeutics EPS ResultsActual EPS$3.80Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AScinai Immunotherapeutics Revenue ResultsActual Revenue$0.27 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AScinai Immunotherapeutics Announcement DetailsQuarterQ4 2025Date4/1/2026TimeAfter Market ClosesConference Call DateWednesday, April 1, 2026Conference Call Time7:00AM ETUpcoming EarningsScinai Immunotherapeutics' Q2 2026 earnings is estimated for Thursday, August 20, 2026, based on past reporting schedules, with a conference call scheduled on Friday, August 21, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (6-K)Annual Report (20-F)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(6-K)Annual report(20-F) Scinai Immunotherapeutics Earnings HeadlinesScinai Immunotherapeutics Ltd. Sponsored ADRAugust 14 at 7:13 AM | edition.cnn.comComparing Agenus (NASDAQ:AGEN) and Scinai Immunotherapeutics (NASDAQ:SCNI)August 14 at 4:15 AM | americanbankingnews.com"Second Wave” Hitting Iran Soon? Wall Street Issues WarningAnalysts at Goldman Sachs and Morgan Stanley are warning that a quiet domestic threat - unrelated to overseas conflict - could be the worst thing to hit American investors in 50 years, potentially keeping portfolios in the red for a decade or more. TradeSmith CEO Keith Kaplan is responding with an AI-driven trading tool built by a former U.S. Air Force nuclear missile coder, designed to sidestep sudden market crashes while still growing your money - regardless of whether markets rise, fall, or stay flat. No options, gold, crypto, or penny stocks involved. | TradeSmith (Ad)Scinai Immunotherapeutics Ltd.: Scinai Strengthens CDMO Leadership with Appointment of Eran Kuratz as Head of Supply Chain and Business Process AdministrationAugust 10, 2026 | finanznachrichten.deScinai Strengthens CDMO Leadership with Appointment of Eran Kuratz as Head of Supply Chain and Business Process AdministrationAugust 10, 2026 | prnewswire.comScinai Immunotherapeutics (NASDAQ:SCNI) Stock to Reverse Split on Friday, August 21stAugust 5, 2026 | americanbankingnews.comSee More Scinai Immunotherapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Scinai Immunotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Scinai Immunotherapeutics and other key companies, straight to your email. Email Address About Scinai ImmunotherapeuticsScinai Immunotherapeutics (NASDAQ:SCNI) Inc is a clinical-stage biotechnology company dedicated to developing novel small-molecule therapies that enhance the immune system’s capacity to recognize and destroy cancer cells. The company’s research emphasizes checkpoint modulation and the discovery of compounds designed to work in concert with established immuno-oncology treatments across a range of solid tumors. Scinai’s pipeline comprises preclinical and early-stage candidates, and the company relies on collaborations with academic institutions and contract research organizations to advance its discovery and development efforts. These partnerships support lead optimization, biomarker identification and the generation of preclinical efficacy and safety data in preparation for eventual clinical evaluation. Headquartered in the United States, Scinai Immunotherapeutics conducts its research and development activities primarily in North America while pursuing strategic alliances to extend its presence into European and Asian markets. The company remains focused on translating its scientific platform into robust therapeutic options, underpinned by rigorous preclinical validation and translational research initiatives.View Scinai Immunotherapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 08/10 - 08/14Applied Materials Beat Everything but Wall Street’s Expectations for MarginsBack From Orbit, Intuitive Machines' Share Price Enters the Buy ZoneCerebras Sells Off After Earnings: Is This a Market Disconnection?Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?Sandisk’s Margins Look Like Software. Can They Last?SpaceX’s First Earnings Report Only Made Wall Street More Divided Upcoming Earnings BHP Group (8/17/2026)Palo Alto Networks (8/17/2026)Home Depot (8/18/2026)Medtronic (8/18/2026)Keysight Technologies (8/18/2026)Lowe's Companies (8/19/2026)TJX Companies (8/19/2026)Target (8/19/2026)Analog Devices (8/19/2026)NetEase (8/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
